Plasma Metabolome Signature in Patients with Early-stage Parkinson Disease (E-pub Ahead of Print)
Elena E Balashova,
Petr G Lokhov,
Dmitry L. Maslov,
Oxana P. Trifonova,
Diana M. Khasanova,
Zuleykha A. Zalyalova,
Razina R. Nigmatullina,
Alexander I. Archakov,
Michael V. Ugrumov.
Background: Recent decades have been marked by advances in omics sciences based on
high-throughput technologies, which have enabled the measurement of enormous numbers of molecules
in biosamples. In metabolomics, a large number of small molecules (metabolome) can be detected in a
single run. The goal of this study was to evaluate the capacity for metabolomic analysis of blood plasma
for early-stage Parkinson disease (PD) diagnosis.
Methods: Blood plasma samples collected from control subjects (n = 20) and patients with PD (Hoehn
and Yahr stages 1, 1.5, and 2; n = 16) were treated with methanol, and low-molecular-weight fractions
were analyzed by direct infusion mass spectrometry. Metabolite ions that exhibited strong association
with PD were included in a diagnostic signature compilation and corresponding characteristics for PD
diagnosis were calculated. For metabolite ions included in the signature, correspondence to specific metabolites
in metabolite databases was established.
Results: A total of 21 metabolite ions that were strongly associated with PD were used to compile a metabolome
signature. The area under a receiver operating characteristic curve (AUC) for PD diagnosis
calculated for the signature was 0.95 (accuracy 94%, specificity 95%, and sensitivity 94%). Metabolites
identified in this study were consistent with factors that had been associated with the development of PD
Conclusion: Direct infusion mass spectrometry of blood plasma metabolites represents a rapid singlestep
method with potential for application in early-stage PD diagnosis.
Keywords: metabolomics, Parkinson&rsquo, s disease, early diagnosis, blood plasma, mass spectrometry
Rights & PermissionsPrintExport